Literature DB >> 2548279

Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease.

A Wlodawer1, M Miller, M Jaskólski, B K Sathyanarayana, E Baldwin, I T Weber, L M Selk, L Clawson, J Schneider, S B Kent.   

Abstract

The rational design of drugs that can inhibit the action of viral proteases depends on obtaining accurate structures of these enzymes. The crystal structure of chemically synthesized HIV-1 protease has been determined at 2.8 angstrom resolution (R factor of 0.184) with the use of a model based on the Rous sarcoma virus protease structure. In this enzymatically active protein, the cysteines were replaced by alpha-amino-n-butyric acid, a nongenetically coded amino acid. This structure, in which all 99 amino acids were located, differs in several important details from that reported previously by others. The interface between the identical subunits forming the active protease dimer is composed of four well-ordered beta strands from both the amino and carboxyl termini and residues 86 to 94 have a helical conformation. The observed arrangement of the dimer interface suggests possible designs for dimerization inhibitors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548279     DOI: 10.1126/science.2548279

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  247 in total

1.  Toxins that are activated by HIV type-1 protease through removal of a signal for degradation by the N-end-rule pathway.

Authors:  P O Falnes; R Welker; H G Kräusslich; S Olsnes
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors:  H C Côté; Z L Brumme; P R Harrigan
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations.

Authors:  L Wang; Y Duan; P Stouten; G V De Lucca; R M Klabe; P A Kollman
Journal:  J Comput Aided Mol Des       Date:  2001-02       Impact factor: 3.686

4.  Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach.

Authors:  A Caflisch; H J Schramm; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

5.  Point mutations and sequence variability in proteins: redistributions of preexisting populations.

Authors:  N Sinha; R Nussinov
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

6.  Thermodynamic linkage between the binding of protons and inhibitors to HIV-1 protease.

Authors:  J Trylska; J Antosiewicz; M Geller; C N Hodge; R M Klabe; M S Head; M K Gilson
Journal:  Protein Sci       Date:  1999-01       Impact factor: 6.725

7.  Genetic selection for dissociative inhibitors of designated protein-protein interactions.

Authors:  S H Park; R T Raines
Journal:  Nat Biotechnol       Date:  2000-08       Impact factor: 54.908

8.  Predicting deleterious amino acid substitutions.

Authors:  P C Ng; S Henikoff
Journal:  Genome Res       Date:  2001-05       Impact factor: 9.043

9.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir.

Authors:  Hironori Hayashi; Nobutoki Takamune; Takashi Nirasawa; Manabu Aoki; Yoshihiko Morishita; Debananda Das; Yasuhiro Koh; Arun K Ghosh; Shogo Misumi; Hiroaki Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.